Impact of the 1000 Genomes Project on the next wave of pharmacogenomic discovery

Pharmacogenomics

Volumn 11, Issue 2, 2010, Pages 249-256

  Zhang, Wei ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Drug response; Genetic variation; HapMap; Lymphoblastoid cell lines; Pharmacogenomics; SNP

Indexed keywords

THIOPURINE METHYLTRANSFERASE;

COPY NUMBER VARIATION; CYTOTOXICITY; DNA SEQUENCE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE LOCUS; GENE SEQUENCE; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC DATABASE; GENETIC VARIABILITY; GENOME; GENOTYPE; HAPLOTYPE; HUMAN; PHARMACOGENOMICS; PHENOTYPE; PLESIOMORPHY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; DRUG DISCOVERY; DRUG THERAPY; GENETIC VARIATION; GENOME, HUMAN; HUMANS; PHARMACOGENETICS;

EID: 77949603244     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.173     Document Type: Review

References (58)

1. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ: Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15), 1549-1563 (2003).
2. Daugaard G: Cisplatin nephrotoxicity: experimental and clinical studies. Dan. Med. Bull. 37(1), 1-12 (1990).
3. Chatelut E, Delord JP, Canal P: Toxicity patterns of cytotoxic drugs. Invest. New Drugs 21(2), 141-148 (2003).
4. Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
5. Zhou S: Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr. Clin. Pharmacol. 1(1), 119-128 (2006).
6. Biason P, Masier S, Toffoli G: UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J. Chemother. 20(2), 158-165 (2008).
7. The International HapMap Consortium: The International Hapmap Project. Nature 426(6968), 789-796 (2003).
8. The International HapMap Consortium: A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005).
9. Van Eerdewegh P, Little RD, Dupuis J et al.: Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418(6896), 426-430 (2002).
10. Binder EB, Holsboer F: Pharmacogenomics and antidepressant drugs. Ann. Med. 38(2), 82-94 (2006).
11. French D, Yang W, Cheng C et al.: Acquired variation outweighs inherited variation in whole genome ana lysis of methotrexate polyglutamate accumulation in leukemia. Blood 113(19), 4512-4520 (2009).
12. Hartford C, Yang W, Cheng C et al.: Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia 21(10), 2128-2136 (2007).
13. Billeci AM, Agnelli G, Caso V: Stroke pharmacogenomics. Expert Opin. Pharmacother. 10(18), 2947-2957 (2009).
14. Mangravite LM, Wilke RA, Zhang J, Krauss RM: Pharmacogenomics of statin response. Curr. Opin. Mol. Ther. 10(6), 555-561 (2008).
15. Zhang W, Duan S, Kistner EO et al.: Evaluation of genetic variation contributing to differences in gene expression between populations. Am. J. Hum. Genet. 82(3), 631-640 (2008).
16. Zhang W, Duan S, Bleibel WK et al.: Identifcation of common genetic variants that account for transcript isoform variation between human populations. Hum. Genet. 125(1), 81-93 (2009).
17. Frazer KA, Ballinger DG, Cox DR et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
18. Peters EJ, Kraja AT, Lin SJ et al.: Association of thymidylate synthase variants with 5-fuorouracil cytotoxicity. Pharmacogenet. Genomics 19(5), 399-401 (2009).
19. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL: Genome-wide discovery of loci infuencing chemotherapy cytotoxicity. Proc. Natl Acad. Sci. USA 101(32), 11809-11814 (2004).
20. Huang RS, Duan S, Bleibel WK et al.: A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl Acad. Sci. USA 104(23), 9758-9763 (2007).
21. Huang RS, Duan S, Shukla SJ et al.: Identifcation of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81(3), 427-437 (2007).
22. Huang RS, Duan S, Kistner EO et al.: Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 68(9), 3161-3168 (2008).
23. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME: Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from africans. Mol. Cancer Ther. 7(9), 3038-3046 (2008).
24. Hartford CM, Duan S, Delaney SM et al.: Population-specifc genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10), 2145-2153 (2009).
25. Aksoy P, Zhu MJ, Kalari KR et al.: Cytosolic 5́-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenet. Genomics 19(8), 567-576 (2009).
26. Li L, Fridley BL, Kalari K et al.: Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 4(11), E7765 (2009).
27. Zhang W, Ratain MJ, Dolan ME: The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics. Bioinform. Biol. Insights 2(1), 15-23 (2008).
28. Zhang W, Dolan ME: Use of cell lines in the investigation of pharmacogenetic loci. Curr. Pharm. Des. 15(32), 3782-3795 (2009).
29. Welsh M, Mangravite L, Medina M et al.: Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 61(4), 413-429 (2009).
30. O'Donnell PH, Dolan ME: Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin. Cancer Res. 15(15), 4806-4814 (2009).
31. Zhang W, Dolan ME: On the challenges of the HapMap resource. Bioinformation 2(6), 238-239 (2008).
32. Cheung VG, Conlin LK, Weber TM et al.: Natural variation in human gene expression assessed in lymphoblastoid cells. Nat. Genet. 33(3), 422-425 (2003).
33. He M, Gitschier J, Zerjal T, de Knijff P, Tyler-Smith C, Xue Y: Geographical affnities of the hapmap samples. PLoS One 4(3), E4684 (2009).
34. Takeuchi F, Serizawa M, Kato N: Hapmap coverage for SNPs in the japanese population. J. Hum. Genet. 53(1), 96-99 (2008).
35. Tantoso E, Yang Y, Li KB: How well do hapmap SNPs capture the untyped SNPs? BMC Genomics 7, 238 (2006).
36. Mardis ER: Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet. 9, 387-402 (2008).
37. Ansorge WJ: Next-generation DNA sequencing techniques. N. Biotechnol. 25(4), 195-203 (2009).
38. Eid J, Fehr A, Gray J et al.: Real-time DNA sequencing from single polymerase molecules. Science 323(5910), 133-138 (2009).
39. Harris TD, Buzby PR, Babcock H et al.: Single-molecule DNA sequencing of a viral genome. Science 320(5872), 106-109 (2008).
40. Huang W, Marth G: Eagleview: A genome assembly viewer for next-generation sequencing technologies. Genome Res. 18(9), 1538-1543 (2008).
41. Bao H, Guo H, Wang J, Zhou R, Lu X, Shi S: Mapview: visualization of short reads alignment on a desktop computer. Bioinformatics 25(12), 1554-1555 (2009).
42. Gamazon ER, Zhang W, Huang RS, Dolan ME, Cox NJ: A pharmacogene database enhanced by the 1000 genomes project. Pharmacogenet. Genomics 19(10), 829-832 (2009).
43. Klein TE, Chang JT, Cho MK et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 1(3), 167-170 (2001).
44. Iafrate AJ, Feuk L, Rivera MN et al.: Detection of large-scale variation in the human genome. Nat. Genet. 36(9), 949-951 (2004).
45. Ashburner M, Ball CA, Blake JA et al.: Gene ontology: tool for the unifcation of biology. The gene ontology consortium. Nat. Genet. 25(1), 25-29 (2000).
46. Gamazon ER, Zhang W, Konkashbaev A et al.: Scan: SNP and copy number annotation. Bioinformatics 26(2), 259-262 (2010).
47. Tishkoff SA, Reed FA, Friedlaender FR et al.: The genetic structure and history of Africans and African Americans. Science 324(5930), 1035-1044 (2009).
48. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG: Common genetic variants account for differences in gene expression among ethnic groups. Nat. Genet. 39(2), 226-231 (2007).
49. Stranger BE, Forrest MS, Dunning M et al.: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315(5813), 848-853 (2007).
50. Hobert O: Gene regulation by transcription factors and microRNAs. Science 319(5871), 1785-1786 (2008).
51. Wolffe A P, Matzke MA: Epigenetics: regulation through repression. Science 286(5439), 481-486 (1999).
52. Ouahchi K, Lindeman N, Lee C: Copy number variants and pharmacogenomics. Pharmacogenomics 7(1), 25-29 (2006).
53. Evans WE, Johnson JA: Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2, 9-39 (2001).
54. Freudenberg-Hua Y, Freudenberg J, Winantea J et al.: Systematic investigation of genetic variability in 111 human genes-implications for studying variable drug response. Pharmacogenomics J. 5(3), 183-192 (2005).
55. Hayden EC: International genome project launched. Nature 451(7177), 378-379 (2008).
56. ENCODE Project Consortium: The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 306(5696), 636-640 (2004).
57. Zhang W, Huang RS, Dolan ME: Integrating epigenomics into pharmacogenomic studies. Pharmgenomics Pers. Med. 1(1), 7-14 (2008).
58. Kent WJ, Sugnet CW, Furey TS et al.: The human genome browser at UCSC. Genome Res. 12(6), 996-1006 (2002).